Below are the most recent publications written about "Interferon-alpha" by people in Profiles.
-
Kr?mer B, Knoll R, Bonaguro L, ToVinh M, Raabe J, Astaburuaga-Garc?a R, Schulte-Schrepping J, Kaiser KM, Rieke GJ, Bischoff J, Monin MB, Hoffmeister C, Schlabe S, De Domenico E, Reusch N, H?ndler K, Reynolds G, Bl?thgen N, Hack G, Finnemann C, Nischalke HD, Strassburg CP, Stephenson E, Su Y, Gardner L, Yuan D, Chen D, Goldman J, Rosenstiel P, Schmidt SV, Latz E, Hrusovsky K, Ball AJ, Johnson JM, Koenig PA, Schmidt FI, Haniffa M, Heath JR, K?mmerer BM, Keitel V, Jensen B, Stubbemann P, Kurth F, Sander LE, Sawitzki B, Aschenbrenner AC, Schultze JL, Nattermann J. Early IFN-a signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19. Immunity. 2021 11 09; 54(11):2650-2669.e14.
-
Seliga A, Lee MH, Fernandes NC, Zuluaga-Ramirez V, Didukh M, Persidsky Y, Potula R, Gallucci S, Sriram U. Kallikrein-Kinin System Suppresses Type I Interferon Responses: A Novel Pathway of Interferon Regulation. Front Immunol. 2018; 9:156.
-
Sise ME, Bloom AK, Wisocky J, Lin MV, Gustafson JL, Lundquist AL, Steele D, Thiim M, Williams WW, Hashemi N, Kim AY, Thadhani R, Chung RT. Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology. 2016 Feb; 63(2):408-17.
-
Litwin AH, Soloway IJ, Cockerham-Colas L, Reynoso S, Heo M, Tenore C, Roose RJ. Successful treatment of chronic hepatitis C with triple therapy in an opioid agonist treatment program. Int J Drug Policy. 2015 Oct; 26(10):1014-9.
-
Qadir A. A Young Lady with Hypertension - Rare Presentation of a Common Disease. J Coll Physicians Surg Pak. 2015 Apr; 25 Suppl 1:S33-5.
-
Lee MJ. Let a hundred flowers bloom: the role of context dependence in creating phenotypic diversity following targeted therapy. Mol Cell. 2015 Mar 05; 57(5):763-764.
-
Sterling RK, Kuo A, Rustgi VK, Sulkowski MS, Stewart TG, Fenkel JM, El-Genaidi H, Mah'moud MA, Abraham GM, Stewart PW, Akushevich L, Nelson DR, Fried MW, Di Bisceglie AM. Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir. Aliment Pharmacol Ther. 2015 Apr; 41(7):671-85.
-
Suschak JJ, Wang S, Fitzgerald KA, Lu S. Identification of Aim2 as a sensor for DNA vaccines. J Immunol. 2015 Jan 15; 194(2):630-6.
-
Narayan K, Waggoner L, Pham ST, Hendricks GL, Waggoner SN, Conlon J, Wang JP, Fitzgerald KA, Kang J. TRIM13 is a negative regulator of MDA5-mediated type I interferon production. J Virol. 2014 Sep; 88(18):10748-57.
-
Di Bisceglie AM, Sulkowski M, Gane E, Jacobson IM, Nelson D, DeSouza C, Alves K, George S, Kieffer T, Zhang EZ, Kauffman R, Asmal M, Koziel MJ. VX-222, a non-nucleoside NS5B polymerase inhibitor, in telaprevir-based regimens for genotype 1 hepatitis C virus infection. Eur J Gastroenterol Hepatol. 2014 Jul; 26(7):761-73.